MY200960A - Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury - Google Patents
Treatments For Heart Failure And Cardiac Ischaemic Reperfusion InjuryInfo
- Publication number
- MY200960A MY200960A MYPI2019002914A MYPI2019002914A MY200960A MY 200960 A MY200960 A MY 200960A MY PI2019002914 A MYPI2019002914 A MY PI2019002914A MY PI2019002914 A MYPI2019002914 A MY PI2019002914A MY 200960 A MY200960 A MY 200960A
- Authority
- MY
- Malaysia
- Prior art keywords
- heart failure
- reperfusion injury
- cardiac
- treatments
- inhibitor
- Prior art date
Links
- 230000000747 cardiac effect Effects 0.000 title abstract 4
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 206010063837 Reperfusion injury Diseases 0.000 title abstract 2
- 230000000302 ischemic effect Effects 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
- A61B17/225—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1619861.6A GB201619861D0 (en) | 2016-11-24 | 2016-11-24 | Treatments for heart failure and cardiac ischaemic reperfusion injury |
| PCT/GB2017/053473 WO2018096319A1 (en) | 2016-11-24 | 2017-11-17 | Treatments for heart failure and cardiac ischaemic reperfusion injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY200960A true MY200960A (en) | 2024-01-26 |
Family
ID=58073526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019002914A MY200960A (en) | 2016-11-24 | 2017-11-17 | Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190374623A1 (https=) |
| EP (1) | EP3544624B1 (https=) |
| JP (1) | JP7231543B2 (https=) |
| KR (1) | KR102678011B1 (https=) |
| CN (1) | CN109996558A (https=) |
| AU (1) | AU2017365926B2 (https=) |
| CA (1) | CA3044624A1 (https=) |
| ES (1) | ES3017482T3 (https=) |
| GB (1) | GB201619861D0 (https=) |
| HR (1) | HRP20250664T1 (https=) |
| HU (1) | HUE071244T2 (https=) |
| MY (1) | MY200960A (https=) |
| PL (1) | PL3544624T3 (https=) |
| RS (1) | RS66778B9 (https=) |
| RU (1) | RU2767445C2 (https=) |
| WO (1) | WO2018096319A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023281447A1 (en) * | 2021-07-07 | 2023-01-12 | Radius Health, Inc. | Methods of treating a cardiovascular ischemic event |
| US20240122794A1 (en) * | 2022-10-12 | 2024-04-18 | Softwave Tissue Regeneration Technologies, Inc. | Acoustic shock wave or pressure pulse treatment and methods of use for anti-aging |
| CN115998768B (zh) * | 2023-02-07 | 2024-01-30 | 西南医科大学 | M2型巨噬细胞外泌体在制备治疗心肌缺血再灌注损伤药物中的应用 |
| CN117257785A (zh) * | 2023-11-09 | 2023-12-22 | 新疆医科大学 | 没食子酸及其衍生物在制备预防和/或治疗心肌损伤药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2007416T3 (pl) * | 2006-04-19 | 2018-05-30 | Ludwig-Maximilians-Universität München | Parathormon (PTH) do zastosowania w leczeniu niedokrwienia |
| US8455435B2 (en) * | 2006-04-19 | 2013-06-04 | Ludwig-Maximilians-Universitat Munchen | Remedies for ischemia |
| MX2011009852A (es) * | 2009-03-27 | 2011-09-29 | Bristol Myers Squibb Co | Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv. |
| EP3110449B1 (en) * | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
-
2016
- 2016-11-24 GB GBGB1619861.6A patent/GB201619861D0/en not_active Ceased
-
2017
- 2017-11-17 PL PL17817018.9T patent/PL3544624T3/pl unknown
- 2017-11-17 EP EP17817018.9A patent/EP3544624B1/en active Active
- 2017-11-17 US US16/463,615 patent/US20190374623A1/en active Pending
- 2017-11-17 RS RS20250446A patent/RS66778B9/sr unknown
- 2017-11-17 KR KR1020197017933A patent/KR102678011B1/ko active Active
- 2017-11-17 MY MYPI2019002914A patent/MY200960A/en unknown
- 2017-11-17 CA CA3044624A patent/CA3044624A1/en active Pending
- 2017-11-17 HU HUE17817018A patent/HUE071244T2/hu unknown
- 2017-11-17 CN CN201780073002.5A patent/CN109996558A/zh active Pending
- 2017-11-17 AU AU2017365926A patent/AU2017365926B2/en not_active Expired - Fee Related
- 2017-11-17 RU RU2019119110A patent/RU2767445C2/ru active
- 2017-11-17 HR HRP20250664TT patent/HRP20250664T1/hr unknown
- 2017-11-17 WO PCT/GB2017/053473 patent/WO2018096319A1/en not_active Ceased
- 2017-11-17 JP JP2019528748A patent/JP7231543B2/ja active Active
- 2017-11-17 ES ES17817018T patent/ES3017482T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| GB201619861D0 (en) | 2017-01-11 |
| RS66778B1 (sr) | 2025-06-30 |
| WO2018096319A1 (en) | 2018-05-31 |
| RU2767445C2 (ru) | 2022-03-17 |
| RU2019119110A3 (https=) | 2021-08-30 |
| JP2020510616A (ja) | 2020-04-09 |
| PL3544624T4 (pl) | 2025-11-03 |
| JP7231543B2 (ja) | 2023-03-01 |
| HUE071244T2 (hu) | 2025-07-28 |
| EP3544624C0 (en) | 2025-02-12 |
| HRP20250664T1 (hr) | 2025-10-24 |
| RU2019119110A (ru) | 2020-12-24 |
| KR20190100199A (ko) | 2019-08-28 |
| PL3544624T3 (pl) | 2025-11-03 |
| US20190374623A1 (en) | 2019-12-12 |
| KR102678011B1 (ko) | 2024-06-25 |
| EP3544624B1 (en) | 2025-02-12 |
| AU2017365926A1 (en) | 2019-07-04 |
| CA3044624A1 (en) | 2018-05-31 |
| ES3017482T3 (en) | 2025-05-13 |
| EP3544624A1 (en) | 2019-10-02 |
| AU2017365926B2 (en) | 2025-06-05 |
| RS66778B9 (sr) | 2025-08-29 |
| CN109996558A (zh) | 2019-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2022005994A (es) | Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras. | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| MX2021002321A (es) | Nuevos metodos. | |
| ZA202202361B (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| MY201603A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| EP4218816A3 (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| BR112018002046A2 (pt) | métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina | |
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| MY200960A (en) | Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury | |
| JOP20200014A1 (ar) | توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| MX2023000610A (es) | Inhibidor de trpv4 como agente terapeutico para enfermedades oculares. | |
| MX2022011725A (es) | Metodos para tratar una lesion pulmonar con inhibidores de cgrp. | |
| HK1255584A1 (zh) | 使用阿坎酸及d-环丝胺酸的联合疗法 | |
| MY186840A (en) | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy | |
| IL272957B2 (en) | Sublingual epinephrine tablets | |
| PL1732551T3 (pl) | Perheksylina do leczenia przewlekłej niewydolności serca | |
| WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
| MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. | |
| HK1225969A1 (zh) | 利用低剂量的拉喹莫德治疗克隆氏病 |